These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 35295337)

  • 1. Candidate Therapeutics by Screening for Multitargeting Ligands: Combining the CB2 Receptor With CB1, PPARγ and 5-HT4 Receptors.
    El-Atawneh S; Goldblum A
    Front Pharmacol; 2022; 13():812745. PubMed ID: 35295337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Novel Cannabinoid CB2 Receptor Agonists from Botanical Compounds and Preliminary Evaluation of Their Anti-Osteoporotic Effects.
    Hu SJ; Cheng G; Zhou H; Zhang Q; Zhang QL; Wang Y; Shen Y; Lian CX; Ma XQ; Zhang QY; Qin LP
    Molecules; 2022 Jan; 27(3):. PubMed ID: 35163968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective Cannabinoid 2 Receptor Agonists as Potential Therapeutic Drugs for the Treatment of Endotoxin-Induced Uveitis.
    Porter RF; Szczesniak AM; Toguri JT; Gebremeskel S; Johnston B; Lehmann C; Fingerle J; Rothenhäusler B; Perret C; Rogers-Evans M; Kimbara A; Nettekoven M; Guba W; Grether U; Ullmer C; Kelly MEM
    Molecules; 2019 Sep; 24(18):. PubMed ID: 31540271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists.
    Yrjölä S; Sarparanta M; Airaksinen AJ; Hytti M; Kauppinen A; Pasonen-Seppänen S; Adinolfi B; Nieri P; Manera C; Keinänen O; Poso A; Nevalainen TJ; Parkkari T
    Eur J Pharm Sci; 2015 Jan; 67():85-96. PubMed ID: 25447744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a CB
    Yang W; Gong X; Sun H; Wu C; Suo J; Ji J; Jiang X; Shen J; He Y; Aisa HA
    Eur J Med Chem; 2024 Feb; 265():116048. PubMed ID: 38150961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elucidation of partial activation of cannabinoid receptor type 2 and identification of potential partial agonists: Molecular dynamics simulation and structure-based virtual screening.
    Uba AI; Aluwala H; Liu H; Wu C
    Comput Biol Chem; 2022 Aug; 99():107723. PubMed ID: 35850049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ligand-Assisted Protein Structure (LAPS): An Experimental Paradigm for Characterizing Cannabinoid-Receptor Ligand-Binding Domains.
    Janero DR; Korde A; Makriyannis A
    Methods Enzymol; 2017; 593():217-235. PubMed ID: 28750804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ligand-based virtual screening identifies a family of selective cannabinoid receptor 2 agonists.
    Gianella-Borradori M; Christou I; Bataille CJ; Cross RL; Wynne GM; Greaves DR; Russell AJ
    Bioorg Med Chem; 2015 Jan; 23(1):241-63. PubMed ID: 25487422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-adamantyl-anthranil amide derivatives: New selective ligands for the cannabinoid receptor subtype 2 (CB2R).
    Graziano G; Delre P; Carofiglio F; Brea J; Ligresti A; Kostrzewa M; Riganti C; Gioè-Gallo C; Majellaro M; Nicolotti O; Colabufo NA; Abate C; Loza MI; Sotelo E; Mangiatordi GF; Contino M; Stefanachi A; Leonetti F
    Eur J Med Chem; 2023 Feb; 248():115109. PubMed ID: 36657299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.
    Davis MP
    Expert Opin Investig Drugs; 2014 Aug; 23(8):1123-40. PubMed ID: 24836296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relevance of Peroxisome Proliferator Activated Receptors in Multitarget Paradigm Associated with the Endocannabinoid System.
    Lago-Fernandez A; Zarzo-Arias S; Jagerovic N; Morales P
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33498245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CB2 receptor-selective agonists as candidates for targeting infection, inflammation, and immunity in SARS-CoV-2 infections.
    Nagoor Meeran MF; Sharma C; Goyal SN; Kumar S; Ojha S
    Drug Dev Res; 2021 Feb; 82(1):7-11. PubMed ID: 33190277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional CB2 type cannabinoid receptors at CNS synapses.
    Morgan NH; Stanford IM; Woodhall GL
    Neuropharmacology; 2009 Sep; 57(4):356-68. PubMed ID: 19616018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice.
    Tai S; Vasiljevik T; Sherwood AM; Eddington S; Wilson CD; Prisinzano TE; Fantegrossi WE
    Drug Alcohol Depend; 2018 Nov; 192():285-293. PubMed ID: 30300803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1,2-Dihydro-2-oxopyridine-3-carboxamides: the C-5 substituent is responsible for functionality switch at CB2 cannabinoid receptor.
    Lucchesi V; Parkkari T; Savinainen JR; Malfitano AM; Allarà M; Bertini S; Castelli F; Del Carlo S; Laezza C; Ligresti A; Saccomanni G; Bifulco M; Di Marzo V; Macchia M; Manera C
    Eur J Med Chem; 2014 Mar; 74():524-32. PubMed ID: 24518874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of cannabinoid CB1 and CB2 receptors expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients' survival.
    Theocharis S; Giaginis C; Alexandrou P; Rodriguez J; Tasoulas J; Danas E; Patsouris E; Klijanienko J
    Tumour Biol; 2016 Mar; 37(3):3647-56. PubMed ID: 26459312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-Based Identification of Potent Natural Product Chemotypes as Cannabinoid Receptor 1 Inverse Agonists.
    Pandey P; Roy KK; Liu H; Ma G; Pettaway S; Alsharif WF; Gadepalli RS; Rimoldi JM; McCurdy CR; Cutler SJ; Doerksen RJ
    Molecules; 2018 Oct; 23(10):. PubMed ID: 30322136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The progress of small molecules against cannabinoid 2 receptor (CB
    Zhang Q; Zhao Y; Wu J; Zhong W; Huang W; Pan Y
    Bioorg Chem; 2024 Mar; 144():107075. PubMed ID: 38218067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding Modes and Selectivity of Cannabinoid 1 (CB1) and Cannabinoid 2 (CB2) Receptor Ligands.
    Yang JF; Williams AH; Penthala NR; Prather PL; Crooks PA; Zhan CG
    ACS Chem Neurosci; 2020 Oct; 11(20):3455-3463. PubMed ID: 32997485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of β-caryophyllene, a dietary cannabinoid.
    Hashiesh HM; Sharma C; Goyal SN; Sadek B; Jha NK; Kaabi JA; Ojha S
    Biomed Pharmacother; 2021 Aug; 140():111639. PubMed ID: 34091179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.